Cannabinoid pharmacology and therapy in gut disorders

Irritable Bowel Syndrome (IBS) and Chronic Constipation

A Rome Working Team Report on Brain-Gut Behavior Therapies for Disorders of Gut-Brain Interaction

Gastroenterology

Keefer L, Ballou SK, Drossman DA, Ringstrom G, Elsenbruch S, Ljótsson B

doi: 10.1053/j.gastro.2021.09.015

Gastroesophageal Reflux Disease (GERD)

Efficacy of Pharmacologic Therapy for Eosinophilic Esophagitis: A Systematic Review and Network Meta-Analysis

J Clin Gastroenterol.

Tomizawa Y, Melek J, Komaki Y, Kavitt RT, Sakuraba A

doi: 10.1097/MCG.

Gastrointestinal Diseases

Gut-focused hypnotherapy for Functional Gastrointestinal Disorders: Evidence-base, practical aspects, and the Manchester Protocol

Neurogastroenterol Motil.

Vasant DH, Whorwell PJ

doi: 10.1111/nmo.13573.

Irritable Bowel Syndrome (IBS) and Chronic Constipation

Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea

Adv Ther.

Brenner DM, Sayuk GS

doi: 10.1007/s12325-019-01116-z.

Irritable Bowel Syndrome (IBS) and Chronic Constipation

Pediatric irritable bowel syndrome and other functional abdominal pain disorders: an update of non-pharmacological treatments

Expert Rev Gastroenterol Hepatol.

Gupta S, Schaffer G, Saps M

doi: 10.1080/

Helicobacter Pylori

Effect of probiotics during vonoprazan-containing triple therapy on gut microbiota in Helicobacter pylori infection: A randomized controlled trial

Helicobacter.

Kakiuchi T, Mizoe A, Yamamoto K, Imamura I, Hashiguchi K, Kawakubo H, Yamaguchi D, Fujioka Y, Nakayama A, Okuda M, Matsuo M

doi: 10.1111/hel.12690.

Inflammatory Bowel Disease

Lower incidence of COVID-19 in patients with inflammatory bowel disease treated with non-gut selective biologic therapy

J Gastroenterol Hepatol

Ardizzone S, Ferretti F, Monico MC, Carvalhas Gabrielli AM, Carmagnola S, Bezzio C, Saibeni S, Bosani M, Caprioli F, Mazza S, Casini V, Cortelezzi CC, Parravicini M, Cassinotti A, Cosimo P, Indriolo A, Di Sabatino A, Lenti MV, Pastorelli L, Conforti F, Ricci C, Sarzi-Puttini P, Vecchi M, Maconi G

doi: 10.1111/jgh.15591

Helicobacter Pylori

Changes in the human gut microbiota composition caused by Helicobacter pylori eradication therapy: A systematic review and meta-analysis

Helicobacter.

Ye Q, Shao X, Shen R, Chen D, Shen J

doi: 10.1111/hel.12713.

Irritable Bowel Syndrome (IBS) and Chronic Constipation

Effect of Antidepressants and Psychological Therapies in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-analysis

Am J Gastroenterol.

Ford AC, Lacy BE, Harris LA, Quigley EM, Moayyedi P

doi: 10.1038/s41395-018-0222-5.

Related content

A Rome Working Team Report on Brain-Gut Behavior Therapies for Disorders of Gut-Brain Interaction

Efficacy of Pharmacologic Therapy for Eosinophilic Esophagitis: A Systematic Review and Network Meta-Analysis

Gut-focused hypnotherapy for Functional Gastrointestinal Disorders: Evidence-base, practical aspects, and the Manchester Protocol

Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea

Pediatric irritable bowel syndrome and other functional abdominal pain disorders: an update of non-pharmacological treatments

Effect of probiotics during vonoprazan-containing triple therapy on gut microbiota in Helicobacter pylori infection: A randomized controlled trial

Lower incidence of COVID-19 in patients with inflammatory bowel disease treated with non-gut selective biologic therapy

Changes in the human gut microbiota composition caused by Helicobacter pylori eradication therapy: A systematic review and meta-analysis

Effect of Antidepressants and Psychological Therapies in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-analysis